AU2003254665C1 - Campylobacter glycans and glycopeptides - Google Patents
Campylobacter glycans and glycopeptides Download PDFInfo
- Publication number
- AU2003254665C1 AU2003254665C1 AU2003254665A AU2003254665A AU2003254665C1 AU 2003254665 C1 AU2003254665 C1 AU 2003254665C1 AU 2003254665 A AU2003254665 A AU 2003254665A AU 2003254665 A AU2003254665 A AU 2003254665A AU 2003254665 C1 AU2003254665 C1 AU 2003254665C1
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- campylobacter
- isolated
- antigen
- galnac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 241000589876 Campylobacter Species 0.000 title claims description 35
- 108010015899 Glycopeptides Proteins 0.000 title description 40
- 102000002068 Glycopeptides Human genes 0.000 title description 40
- 108090000623 proteins and genes Proteins 0.000 claims description 60
- 150000004676 glycans Chemical class 0.000 claims description 56
- 239000012634 fragment Substances 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 37
- 241000589875 Campylobacter jejuni Species 0.000 claims description 34
- 102000003886 Glycoproteins Human genes 0.000 claims description 28
- 108090000288 Glycoproteins Proteins 0.000 claims description 28
- 244000144972 livestock Species 0.000 claims description 28
- 241001465754 Metazoa Species 0.000 claims description 23
- 239000000427 antigen Substances 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 244000052769 pathogen Species 0.000 claims description 21
- 230000027455 binding Effects 0.000 claims description 20
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 18
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 16
- PZUPAGRIHCRVKN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]-5-[3,4,5-trihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound OCC1OC(O)C(O)C(O)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(COC4C(C(O)C(O)CO4)O)O3)O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(COC2C(C(O)C(O)CO2)O)O1 PZUPAGRIHCRVKN-UHFFFAOYSA-N 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 239000000523 sample Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 241000894006 Bacteria Species 0.000 claims description 11
- 241000196324 Embryophyta Species 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 229960005486 vaccine Drugs 0.000 claims description 11
- 241000282412 Homo Species 0.000 claims description 10
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 229940024606 amino acid Drugs 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 7
- 108010038807 Oligopeptides Proteins 0.000 claims description 7
- 102000015636 Oligopeptides Human genes 0.000 claims description 7
- 238000011109 contamination Methods 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 6
- 244000144977 poultry Species 0.000 claims description 5
- 241000282826 Camelus Species 0.000 claims description 4
- 210000003608 fece Anatomy 0.000 claims description 4
- 239000010871 livestock manure Substances 0.000 claims description 4
- 206010051226 Campylobacter infection Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003673 groundwater Substances 0.000 claims description 3
- 229960001438 immunostimulant agent Drugs 0.000 claims description 3
- 239000003022 immunostimulating agent Substances 0.000 claims description 3
- 230000003308 immunostimulating effect Effects 0.000 claims description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- NRXWTRNYICXMBF-CACQUXPASA-N n-[(2r,3s,4s,5r)-5-acetamido-4,6-dihydroxy-2-methyloxan-3-yl]acetamide Chemical compound C[C@H]1OC(O)[C@H](NC(C)=O)[C@@H](O)[C@@H]1NC(C)=O NRXWTRNYICXMBF-CACQUXPASA-N 0.000 claims description 2
- 238000004091 panning Methods 0.000 claims description 2
- 239000002689 soil Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 238000009007 Diagnostic Kit Methods 0.000 claims 2
- 241000282842 Lama glama Species 0.000 claims 1
- 241001416177 Vicugna pacos Species 0.000 claims 1
- 241000282840 Vicugna vicugna Species 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 40
- 102000004169 proteins and genes Human genes 0.000 description 40
- 238000001228 spectrum Methods 0.000 description 37
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 29
- 238000004458 analytical method Methods 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 23
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 20
- 239000000499 gel Substances 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 19
- 239000000284 extract Substances 0.000 description 17
- 238000002156 mixing Methods 0.000 description 17
- 238000004008 high resolution magic-angle spinning Methods 0.000 description 16
- 150000002500 ions Chemical class 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000001551 total correlation spectroscopy Methods 0.000 description 12
- 230000013595 glycosylation Effects 0.000 description 11
- 238000005080 one-dimensional TOCSY Methods 0.000 description 11
- 238000004885 tandem mass spectrometry Methods 0.000 description 11
- 239000004471 Glycine Substances 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 150000002482 oligosaccharides Polymers 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 108010048090 soybean lectin Proteins 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 229920001542 oligosaccharide Polymers 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
- 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 238000005004 MAS NMR spectroscopy Methods 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 238000012512 characterization method Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- -1 protonated glycopeptide ion Chemical class 0.000 description 7
- 238000004791 1D NOESY Methods 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 108090001090 Lectins Proteins 0.000 description 6
- 102000004856 Lectins Human genes 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 239000002523 lectin Substances 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241000589877 Campylobacter coli Species 0.000 description 5
- 238000001042 affinity chromatography Methods 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000012521 purified sample Substances 0.000 description 5
- 238000012582 total correlation spectroscopy experiment Methods 0.000 description 5
- LEJHBBPEPOZERQ-RSVSWTKNSA-N (3r,4s,5s,6r)-3,5-diamino-6-methyloxane-2,4-diol Chemical compound C[C@H]1OC(O)[C@H](N)[C@@H](O)[C@@H]1N LEJHBBPEPOZERQ-RSVSWTKNSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acetylhexosamine Chemical compound CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
- 108010059712 Pronase Proteins 0.000 description 4
- 238000005277 cation exchange chromatography Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 241001515965 unidentified phage Species 0.000 description 4
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 3
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 3
- 241000282838 Lama Species 0.000 description 3
- 238000012565 NMR experiment Methods 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 3
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 3
- 239000001099 ammonium carbonate Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000001360 collision-induced dissociation Methods 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 3
- 238000012585 nuclear overhauser effect spectroscopy experiment Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- BUAQBZPEZUPDRF-RHQZKXFESA-N (2r,3r,4r,5r,6s)-2-(hydroxymethyl)-6-[(2-hydroxy-7,8,9,10-tetrahydro-6h-benzo[c]chromen-3-yl)oxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1C(CCCC1)=C1CO2 BUAQBZPEZUPDRF-RHQZKXFESA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000203069 Archaea Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001302160 Escherichia coli str. K-12 substr. DH10B Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000010828 animal waste Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 230000007073 chemical hydrolysis Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 244000078673 foodborn pathogen Species 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000005858 glycosidation reaction Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 229940030980 inova Drugs 0.000 description 2
- 101150029836 kpsM gene Proteins 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- LYUGPLUDRALHKJ-UHFFFAOYSA-N 1-(cyclohexylamino)propane-1-sulfonic acid Chemical compound CCC(S(O)(=O)=O)NC1CCCCC1 LYUGPLUDRALHKJ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 241000589874 Campylobacter fetus Species 0.000 description 1
- 101100388090 Campylobacter jejuni subsp. jejuni serotype O:2 (strain ATCC 700819 / NCTC 11168) dps gene Proteins 0.000 description 1
- 101100460019 Campylobacter jejuni subsp. jejuni serotype O:2 (strain ATCC 700819 / NCTC 11168) ndk gene Proteins 0.000 description 1
- 101100341097 Campylobacter jejuni subsp. jejuni serotype O:2 (strain ATCC 700819 / NCTC 11168) ppa gene Proteins 0.000 description 1
- 101100171900 Campylobacter jejuni subsp. jejuni serotype O:2 (strain ATCC 700819 / NCTC 11168) tsf gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108010089072 Dolichyl-diphosphooligosaccharide-protein glycotransferase Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010090127 Periplasmic Proteins Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101150099625 STT3 gene Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101710100170 Unknown protein Proteins 0.000 description 1
- 241001416176 Vicugna Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- AFVLVVWMAFSXCK-VMPITWQZSA-N alpha-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(\C#N)=C\C1=CC=C(O)C=C1 AFVLVVWMAFSXCK-VMPITWQZSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940015062 campylobacter jejuni Drugs 0.000 description 1
- 238000004850 capillary HPLC Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 244000000021 enteric pathogen Species 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000002170 nanoflow liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 238000012587 nuclear overhauser effect experiment Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000000955 peptide mass fingerprinting Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000004104 two-dimensional total correlation spectroscopy Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56922—Campylobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39973502P | 2002-08-01 | 2002-08-01 | |
| US60/399,735 | 2002-08-01 | ||
| PCT/CA2003/001156 WO2004013151A2 (en) | 2002-08-01 | 2003-07-30 | Campylobacter glycans and glycopeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2003254665A1 AU2003254665A1 (en) | 2004-02-23 |
| AU2003254665B2 AU2003254665B2 (en) | 2010-01-28 |
| AU2003254665C1 true AU2003254665C1 (en) | 2010-08-19 |
Family
ID=31495764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003254665A Expired AU2003254665C1 (en) | 2002-08-01 | 2003-07-30 | Campylobacter glycans and glycopeptides |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7598354B2 (enExample) |
| EP (1) | EP1527080B1 (enExample) |
| JP (1) | JP4718174B2 (enExample) |
| CN (1) | CN1671722A (enExample) |
| AU (1) | AU2003254665C1 (enExample) |
| BR (1) | BR0312896A (enExample) |
| CA (1) | CA2494223C (enExample) |
| ES (1) | ES2391525T3 (enExample) |
| WO (1) | WO2004013151A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214660B2 (en) * | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| CA2477794C (en) | 2002-03-07 | 2013-08-20 | Eidgenoessische Technische Hochschule Zuerich | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| AU2002952121A0 (en) * | 2002-10-17 | 2002-10-31 | Alchemia Limited | Novel carbohydrate based anti-bacterials |
| SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
| WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US20080015142A1 (en) * | 2003-12-03 | 2008-01-17 | Defrees Shawn | Glycopegylated Follicle Stimulating Hormone |
| US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
| HUE026826T2 (en) | 2004-10-29 | 2016-07-28 | Ratiopharm Gmbh | Modeling and glycopegylation of fibroblast growth factor (FGF) |
| US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| EP1871795A4 (en) | 2005-04-08 | 2010-03-31 | Biogenerix Ag | COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE |
| JP5356807B2 (ja) | 2005-05-11 | 2013-12-04 | アイトヘネーシシェ テフニーシェ ホフシューレ チューリッヒ | 原核細胞由来の組み換えｎ−グリコシル化タンパク質 |
| US20070105755A1 (en) * | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
| US20080248959A1 (en) | 2006-07-21 | 2008-10-09 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー／エス | ポリペプチドコンジュゲートの精製方法 |
| RS52845B (sr) | 2007-04-03 | 2013-12-31 | Biogenerix Ag | Postupci tretmana korišćenjem glikopegiliranog g-csf |
| JP5876649B2 (ja) | 2007-06-12 | 2016-03-02 | ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ | ヌクレオチド糖の改良製造法 |
| US8999668B2 (en) | 2008-01-03 | 2015-04-07 | Cornell Research Foundation, Inc. | Glycosylated protein expression in prokaryotes |
| EP2242505A4 (en) * | 2008-01-08 | 2012-03-07 | Biogenerix Ag | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES |
| HRP20181259T1 (hr) | 2008-02-20 | 2018-10-05 | Glaxosmithkline Biologicals S.A. | Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica |
| ES2476690T3 (es) | 2008-02-27 | 2014-07-15 | Novo Nordisk A/S | Moléculas conjugadas del Factor VIII |
| PL2411503T3 (pl) * | 2009-03-27 | 2018-01-31 | Eidgenoessische Technische Hochschule Zuerich | Salmonella enterica prezentująca n-glikan z c. jejuni lub jego pochodne |
| AU2010322454B2 (en) | 2009-11-19 | 2016-05-19 | Glaxosmithkline Biologicals S.A. | Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells |
| JP5925699B2 (ja) * | 2010-02-11 | 2016-05-25 | ザ・ガバナーズ・オブ・ザ・ユニバーシティー・オブ・アルバータ | Ｎ結合型グリカン化合物 |
| US8841099B2 (en) * | 2010-04-20 | 2014-09-23 | National Research Council Of Canada | Cell-based production of nonulosonates |
| ES2844596T3 (es) | 2010-05-06 | 2021-07-22 | Glaxosmithkline Biologicals Sa | Vacunas de bioconjugados de bacterias grampositivas capsulares |
| US9308246B2 (en) | 2010-05-28 | 2016-04-12 | The United States Of America As Represented By The Secretary Of The Navy | Capsule composition for use as immunogen against Campylobacter jejuni |
| JP6135046B2 (ja) * | 2012-04-20 | 2017-05-31 | 株式会社島津製作所 | 糖ペプチドの質量分析法 |
| EP2991675B1 (en) | 2013-04-05 | 2019-07-24 | The Governors of the University of Alberta | Campylobacter vaccine |
| EP4205553A1 (en) * | 2015-01-26 | 2023-07-05 | DSM Nutritional Products, LLC | Oligosaccharide compositions for use animal feed and methods of producing thereof |
| WO2017117539A1 (en) | 2015-12-30 | 2017-07-06 | Northwestern University | Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation |
| US10829795B2 (en) | 2016-07-14 | 2020-11-10 | Northwestern University | Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates |
| US11898187B2 (en) | 2017-08-15 | 2024-02-13 | Northwestern University | Protein glycosylation sites by rapid expression and characterization of N-glycosyltransferases |
| WO2019119134A1 (en) * | 2017-12-19 | 2019-06-27 | The Governors Of The University Of Alberta | Clostridium perfringens surface glycans and uses thereof |
| US11530432B2 (en) | 2018-03-19 | 2022-12-20 | Northwestern University | Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates |
| US11725224B2 (en) | 2018-04-16 | 2023-08-15 | Northwestern University | Methods for co-activating in vitro non-standard amino acid (nsAA) incorporation and glycosylation in crude cell lysates |
| WO2020072127A2 (en) | 2018-08-03 | 2020-04-09 | Northwestern University | On demand, portable, cell-free molecular sensing platform |
| US12404533B2 (en) | 2019-01-11 | 2025-09-02 | Northwestern University | Bioconjugate vaccines' synthesis in prokaryotic cell lysates |
| US12325884B2 (en) | 2019-03-04 | 2025-06-10 | Northwestern University | Riboswitch-based fluoride sensing in cell-free extract |
| US12226410B2 (en) | 2019-10-18 | 2025-02-18 | Northwestern University | Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6 |
| US20240287564A1 (en) * | 2021-06-07 | 2024-08-29 | The University Of British Columbia | Acholetin biopolymers and methods for enzymatic synthesis |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4925796A (en) * | 1986-03-07 | 1990-05-15 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| US5200344A (en) * | 1990-11-13 | 1993-04-06 | Blaser Martin J | Diagnostic testing for campylobacter jejuni or campylobacter coli infections using novel antigens |
| WO1995005850A1 (en) * | 1993-08-27 | 1995-03-02 | Enteric Research Laboratories, Inc. | Campylobacter jejuni antigens, and methods for their production and use |
| WO1996007753A1 (en) * | 1994-09-06 | 1996-03-14 | Bioflexin Ab | Amino acid conjugate |
| US5840547A (en) * | 1995-01-05 | 1998-11-24 | Ramot University Authority For Applied Research & Indfustrial Development Ltd. | Bioemulsifiers |
| US6676946B2 (en) * | 1997-03-27 | 2004-01-13 | Institut Pasteur | Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof |
| US6699705B2 (en) * | 1999-02-01 | 2004-03-02 | National Research Council Of Canada | Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics |
| AU3513500A (en) * | 1999-03-05 | 2000-09-21 | Trustees Of Tufts College | Emulsan and emulsan analogs immunization formulations and use |
| US6512014B2 (en) * | 2000-12-13 | 2003-01-28 | Ramot University Authority For Applied Research And Industrial Development Limited | Compositions containing bioemulsifiers and a method for their preparation |
| ES2561985T3 (es) * | 2001-10-10 | 2016-03-01 | Ratiopharm Gmbh | Remodelación y glicoconjugación de anticuerpos |
| US20030232401A1 (en) * | 2002-06-12 | 2003-12-18 | Pugia Michael J. | Bacterial test method by glycated label binding |
| US9084809B2 (en) * | 2005-09-21 | 2015-07-21 | The United States Of America As Represented By The Secretary Of The Navy | Immunogenic capsule composition for use as a vaccine component against Campylobacter jejuni |
-
2003
- 2003-07-30 CN CNA038181851A patent/CN1671722A/zh active Pending
- 2003-07-30 EP EP03766087A patent/EP1527080B1/en not_active Expired - Lifetime
- 2003-07-30 US US10/523,459 patent/US7598354B2/en not_active Expired - Lifetime
- 2003-07-30 WO PCT/CA2003/001156 patent/WO2004013151A2/en not_active Ceased
- 2003-07-30 AU AU2003254665A patent/AU2003254665C1/en not_active Expired
- 2003-07-30 CA CA2494223A patent/CA2494223C/en not_active Expired - Lifetime
- 2003-07-30 JP JP2004525093A patent/JP4718174B2/ja not_active Expired - Fee Related
- 2003-07-30 ES ES03766087T patent/ES2391525T3/es not_active Expired - Lifetime
- 2003-07-30 BR BR0312896-2A patent/BR0312896A/pt not_active IP Right Cessation
Non-Patent Citations (2)
| Title |
|---|
| Linton, D. et al. (2002) Molecular Microbiology 43: 497-508 * |
| Schwerer, B. et al. (1995) Journal of Endotoxin Research 2: 395-403 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20060165728A1 (en) | 2006-07-27 |
| BR0312896A (pt) | 2005-06-14 |
| JP2005534752A (ja) | 2005-11-17 |
| US7598354B2 (en) | 2009-10-06 |
| ES2391525T3 (es) | 2012-11-27 |
| JP4718174B2 (ja) | 2011-07-06 |
| EP1527080B1 (en) | 2012-06-20 |
| AU2003254665B2 (en) | 2010-01-28 |
| CA2494223A1 (en) | 2004-02-12 |
| WO2004013151A3 (en) | 2004-07-01 |
| AU2003254665A1 (en) | 2004-02-23 |
| EP1527080A2 (en) | 2005-05-04 |
| WO2004013151A2 (en) | 2004-02-12 |
| CA2494223C (en) | 2012-10-02 |
| CN1671722A (zh) | 2005-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003254665C1 (en) | Campylobacter glycans and glycopeptides | |
| JP7370391B2 (ja) | 大腸菌ｏ抗原多糖のバイオコンジュゲート、その製造方法およびその使用方法 | |
| Iwashkiw et al. | Exploiting the Campylobacter jejuni protein glycosylation system for glycoengineering vaccines and diagnostic tools directed against brucellosis | |
| JP7589164B2 (ja) | 大腸菌ｏ抗原多糖のバイオコンジュゲートを製造する方法、その組成物およびその使用方法 | |
| Dube et al. | Chemical tools to discover and target bacterial glycoproteins | |
| Keenan et al. | Alterations in Helicobacter pylori outer membrane and outer membrane vesicle-associated lipopolysaccharides under iron-limiting growth conditions | |
| US20160136285A1 (en) | An isolated immunogenic bacterial antigen and its use in the prevention and treatment of infections caused by gram-negative bacteria | |
| Kubler-Kielb et al. | Saccharide/protein conjugate vaccines for Bordetella species: preparation of saccharide, development of new conjugation procedures, and physico-chemical and immunological characterization of the conjugates | |
| WO2012106251A2 (en) | Pertussis vaccine | |
| CA2789505C (en) | N-linked glycan compounds | |
| EP3535276A2 (en) | Capped oligosaccharides comprising seven or more units of 4,6-dideoxy-4-acylamido-alpha-pyranose and conjugates thereof as vaccines against infections caused by brucella organisms | |
| US5541075A (en) | Carbohydrate-based vaccine and diagnostic reagent for trichinosis | |
| Monteiro et al. | Synthesis and immunogenicity of a Helicobacter pylori lipopolysaccharide-based conjugate | |
| Zhang et al. | Structural characterization of a novel pentasaccharide repeating unit from Burkholderia pseudomallei strain BPC006 and its role in diagnosis and immunogenicity | |
| US10364298B2 (en) | Clostridium difficile lipoteichoic acid and uses thereof | |
| EP1747262B1 (en) | Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates | |
| US20150322176A1 (en) | Novel polysaccharide immunogens from clostridium bolteae isolated from autistic subjects and methods and uses thereof | |
| Xiao et al. | Antigenicity evaluation of synthetic α-(1, 3)-linked D, D-heptoglycan of Helicobacter pylori serotype O6 lipopolysaccharide | |
| Duncombe | Characterisation of a unique epitope at the non-reducing end of the Brucella O-polysaccharide | |
| EA046636B1 (ru) | Способы получения биоконъюгатов полисахаридных о-антигенов e. coli, их композиции и способы их применения | |
| WO2009033269A1 (en) | Novel polysaccharide immunogens from alloiococcus otitidis and synthesis of a glycoconjugate vaccine thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 08 APR 2010. |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 08 APR 2010 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |